B

Biohit Oyj
OMXH:BIOBV

Watchlist Manager
Biohit Oyj
OMXH:BIOBV
Watchlist
Price: 2.3 EUR Market Closed
Market Cap: 34.8m EUR
Have any thoughts about
Biohit Oyj?
Write Note

Biohit Oyj
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biohit Oyj
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
B
Biohit Oyj
OMXH:BIOBV
Current Portion of Long-Term Debt
€300k
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
-3%
R
Revenio Group Oyj
OMXH:REG1V
Current Portion of Long-Term Debt
€5.5m
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
25%
M
Modulight Oyj
OMXH:MODU
Current Portion of Long-Term Debt
€2m
CAGR 3-Years
18%
CAGR 5-Years
96%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Current Portion of Long-Term Debt
€375k
CAGR 3-Years
70%
CAGR 5-Years
62%
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Current Portion of Long-Term Debt
€1.3m
CAGR 3-Years
46%
CAGR 5-Years
27%
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Current Portion of Long-Term Debt
€1.5m
CAGR 3-Years
42%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Biohit Oyj
Glance View

Market Cap
34.9m EUR
Industry
Health Care

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

BIOBV Intrinsic Value
3.35 EUR
Undervaluation 31%
Intrinsic Value
Price
B

See Also

What is Biohit Oyj's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
300k EUR

Based on the financial report for Jun 30, 2024, Biohit Oyj's Current Portion of Long-Term Debt amounts to 300k EUR.

What is Biohit Oyj's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-3%

Over the last year, the Current Portion of Long-Term Debt growth was 0%. The average annual Current Portion of Long-Term Debt growth rates for Biohit Oyj have been 14% over the past three years , 8% over the past five years , and -3% over the past ten years .

Back to Top